Therapy Areas: Inflammatory Diseases
Sanofi and Regeneron's Dupixent gains Japan approval for paediatric asthma patients aged 6 to 11
23 December 2025 - French healthcare company Sanofi S.A. (Euronext Paris:SAN) (Nasdaq:SNY) and US biotechnology company Regeneron Pharmaceuticals Inc (Nasdaq:REGN) on Tuesday announced approval from J...
Aqualung Therapeutics' Phase 2a lung fibrosis study approved by US FDA
23 December 2025 - Clinical-stage immunotherapeutics company Aqualung Therapeutics announced on Monday that it has received approval from the US Food and Drug Administration (FDA) for a Phase 2a study...
Alvotech launches first-in-market golimumab biosimilar in Europe
22 December 2025 - Global biotechnology company Alvotech S.A. (NASDAQ:ALVO) announced on Monday the European launch of Gobivaz (golimumab), its biosimilar to Simponi (golimumab), also known as AVT05 (...
Physiomics secures follow-on UK contract for Phase 2 study support
15 December 2025 - Physiomics plc (AIM: PYC), a mathematical modelling, data science and biostatistics company, announced on Monday that it has been awarded a follow-on contract with an existing UK cl...
RedHill Biopharma reports positive opaganib data in venetoclax-resistant CLL
15 December 2025 - Biopharmaceutical company RedHill Biopharma Ltd (Nasdaq: RDHL) on Monday reported positive in vivo results showing that opaganib, when combined with venetoclax, reduced Chronic Lymp...
InduPro secures strategic investment and collaboration with Sanofi to advance autoimmune therapy
10 December 2025 - Biotechnology company InduPro Inc announced on Wednesday that it has entered into a strategic equity investment and research collaboration with French healthcare company Sanofi S.A....